Wendt, Frank R. http://orcid.org/0000-0002-2108-6822
Pathak, Gita A.
Lencz, Todd http://orcid.org/0000-0001-8586-338X
Krystal, John H.
Gelernter, Joel http://orcid.org/0000-0002-4067-1859
Polimanti, Renato http://orcid.org/0000-0003-0745-6046
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Deafness and Other Communication Disorders
American Foundation for Suicide Prevention
Simons Foundation
Article History
Received: 6 April 2020
Accepted: 21 September 2020
First Online: 21 December 2020
Competing interests
: J.H.K. reports compensation as the editor of <i>Biological Psychiatry</i> and also serves on the Scientific Advisory Boards for Bioasis Technologies, Inc., Biohaven Pharmaceuticals, BioXcel Therapeutics, Inc. (Clinical Advisory Board), Cadent Therapeutics (Clinical Advisory Board), PsychoGenics, Inc, Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, and the Lohocla Research Corporation. He owns stock in ArRETT Neuroscience, Inc., Biohaven Pharmaceuticals, Sage Pharmaceuticals and Spring Care, Inc. and stock options in Biohaven Pharmaceuticals Medical Sciences, BlackThorn Therapeutics, Inc. and Storm Biosciences, Inc. He is co-inventor on multiple patents as listed below: (1) Seibyl J. P., Krystal J. H., Charney D. S. Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia. US patent 5,447,948 (1995); (2) Vladimir, C., Krystal, J. H., Sanacora, G. Glutamate modulating agents in the treatment of mental disorders, US patent 8,778,979 (2014); (3) Charney D., Krystal J. H., Manji H., Matthew S., Zarate C. Intranasal administration of ketamine to treat depression US patent application 14/197,767 (2014); (4) Zarate, C., Charney, D. S., Manji, H. K., Mathew, S. J., Krystal, J. H., Department of Veterans Affairs. Methods for treating suicidal ideation, US patent application no. 14/197,767 (2014); (5) Arias A., Petrakis I., Krystal J. H. Composition and methods to treat addiction. US patent application no. 61/973/961 (2014); (6) Chekroud, A., Gueorguieva, R., Krystal, J. H. Treatment selection for major depressive disorder (filing date 2016, USPTO docket number Y0087.70116US00). Provisional patent submission by Yale University: (7) Gihyun, Y., Petrakis I., Krystal, J. H. Compounds, compositions and methods for treating or preventing depression and other diseases. US provisional patent application no. 62/444,552 (filed 10 January 2017) by Yale University Office of Cooperative Research OCR 7088 US01: (8) Abdallah, C., Krystal, J. H., Duman, R., Sanacora, G. Combination therapy for treating or preventing depression or other mood diseases. US provisional patent application no. 047162-7177P1 (00754) filed on 20 August 2018 by Yale University Office of Cooperative Research OCR 7451 US01. J.G. is named as an inventor on PCT patent application 15/878,640 Genotype-guided dosing of opioid agonists, filed 24 January 2018. J.G. and R.P. are paid for their editorial work on the journal <i>Complex Psychiatry</i>. The other authors declare no competing interests.